(ZQQ) BMO NASDAQ 100 Equity (CAD - Ratings and Ratios
ETF, US Equity, CAD Hedged, NASDAQ Stocks, Currency Hedging
Description: ZQQ BMO NASDAQ 100 Equity (CAD
The BMO Nasdaq100 Equity Hedged to CAD Index ETF is designed to mirror the performance of the NASDAQ-100 Index, with its U.S. dollar exposure hedged back to Canadian dollars, thereby minimizing currency risk for Canadian investors. This ETF achieves its objective by holding the constituent securities of the NASDAQ-100 Index in proportion to their representation in the index.
The NASDAQ-100 Index is a basket of the 100 largest and most actively traded U.S. companies listed on the NASDAQ stock exchange, with a heavy weighting towards technology and growth stocks. By investing in ZQQ, Canadian investors gain exposure to these leading U.S. companies, including tech giants like Apple, Microsoft, and Alphabet, while mitigating the impact of USD/CAD exchange rate fluctuations.
Analyzing the technical data, we observe that the ETFs price is currently above its 20-day, 50-day, and 200-day simple moving averages (SMA20, SMA50, SMA200), indicating a positive trend. The Average True Range (ATR) is 2.05, representing 1.35% of the last price, suggesting moderate volatility. Given the 52-week high and low, the ETF is near its all-time high, indicating strong performance over the past year.
From a fundamental perspective, the Assets Under Management (AUM) stand at CAD 2006.05 million, indicating a sizable and liquid ETF. The funds focus on the NASDAQ-100 Index, which is known for its growth and innovation, positions it well for potential long-term growth, especially if the tech sector continues to outperform.
Forecasting future performance using both technical and fundamental data, we can anticipate that ZQQ will continue on its upward trajectory if the NASDAQ-100 Index maintains its momentum. The hedging to CAD reduces currency risk, making it an attractive option for Canadian investors seeking exposure to U.S. tech and growth stocks. However, investors should be cautious of potential volatility and market corrections. A break below the SMA50 could signal a shift in trend, while sustained AUM growth and a continued rise above the SMA20 could reinforce the bullish outlook.
Additional Sources for ZQQ ETF
ZQQ ETF Overview
Market Cap in USD | 1,791m |
Category | US Equity |
IPO / Inception | 2010-01-19 |
ZQQ ETF Ratings
Growth Rating | 66.0 |
Fundamental | - |
Dividend Rating | 41.5 |
Rel. Strength | -1.93 |
Analysts | - |
Fair Price Momentum | 148.06 CAD |
Fair Price DCF | - |
ZQQ Dividends
Dividend Yield 12m | 0.35% |
Yield on Cost 5y | 0.67% |
Annual Growth 5y | 7.20% |
Payout Consistency | 79.8% |
Payout Ratio | % |
ZQQ Growth Ratios
Growth Correlation 3m | 97.2% |
Growth Correlation 12m | 49.7% |
Growth Correlation 5y | 73.7% |
CAGR 5y | 14.95% |
CAGR/Max DD 5y | 0.41 |
Sharpe Ratio 12m | 1.26 |
Alpha | 2.11 |
Beta | 1.248 |
Volatility | 11.13% |
Current Volume | 23.3k |
Average Volume 20d | 15.1k |
Stop Loss | 155.3 (-3%) |
As of August 02, 2025, the stock is trading at CAD 160.13 with a total of 23,345 shares traded.
Over the past week, the price has changed by -0.05%, over one month by +2.21%, over three months by +18.03% and over the past year by +18.30%.
Yes. Based on ValueRay's Analyses, BMO NASDAQ 100 Equity (CAD (TO:ZQQ) is currently (August 2025) a good stock to buy. It has a ValueRay Growth Rating of 65.99 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZQQ is around 148.06 CAD . This means that ZQQ is currently overvalued and has a potential downside of -7.54%.
BMO NASDAQ 100 Equity (CAD has no consensus analysts rating.
According to our own proprietary Forecast Model, ZQQ BMO NASDAQ 100 Equity (CAD will be worth about 177.7 in August 2026. The stock is currently trading at 160.13. This means that the stock has a potential upside of +10.95%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 177.7 | 11% |